FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044891199> ?p ?o ?g. }

• W3044891199 endingPage "5802" @default.
• W3044891199 startingPage "5793" @default.
• W3044891199 abstract "Shingles is a painful, blistering rash caused by reactivation of latent varicella-zoster virus (VZV) and most frequently occurs in elderly and immunocompromised individuals. Currently, two approved vaccines for the prevention of shingles are on the market, a live attenuated virus vaccine ZOSTAVAX® (Merck & Co., Inc., Kenilworth, NJ, USA) and an AS01B adjuvanted subunit protein vaccine Shingrix™ (Glaxo Smith Kline, Rockville, MD, USA). Human clinical immunogenicity and vaccine efficacy data is available for these two benchmark vaccines, offering a unique opportunity for comparative analyses with novel vaccine platforms and animal model translatability studies. The studies presented here utilized non-human primates (NHP) to evaluate humoral and cellular immune response by three vaccine modalities: the new platform of lipid nanoparticle (LNP) formulated mRNA encoding VZV gE antigen (VZV gE mRNA/LNP) as compared with well-established platforms of live attenuated VZV (VZV LAV) and adjuvanted VZV gE subunit protein (VZV gE protein/adjuvant). The magnitude of response to vaccination with a single 100–200 μg mRNA dose or two 50 μg mRNA doses of VZV gE mRNA/LNP were comparable to two 50 μg protein doses of VZV gE protein/adjuvant, suggesting the VZV gE mRNA/LNP platform has the potential to elicit a robust immune response, and both modalities generated markedly higher responses than VZV LAV. Additionally, the slopes of decay for VZV-specific antibody titers were roughly similar across all three vaccines, indicating the magnitude of peak immunogenicity was the driving force in determining immune response longevity. Finally, vaccine-induced immunogenicity with VZV LAV and VZV gE protein/adjuvant in NHP closely resembled human clinical trials immune response data for ZOSTAVAX® and Shingrix™, helping to validate NHP as an appropriate preclinical model for evaluating these vaccines." @default.
• W3044891199 created "2020-07-29" @default.
• W3044891199 creator A5002087699 @default.
• W3044891199 creator A5002893062 @default.
• W3044891199 creator A5004378183 @default.
• W3044891199 creator A5005980025 @default.
• W3044891199 creator A5006998638 @default.
• W3044891199 creator A5009712443 @default.
• W3044891199 creator A5025263395 @default.
• W3044891199 creator A5026305333 @default.
• W3044891199 creator A5027000499 @default.
• W3044891199 creator A5029641140 @default.
• W3044891199 creator A5048700949 @default.
• W3044891199 creator A5054754600 @default.
• W3044891199 creator A5071048429 @default.
• W3044891199 creator A5075133911 @default.
• W3044891199 creator A5088571596 @default.
• W3044891199 date "2020-08-01" @default.
• W3044891199 modified "2023-10-09" @default.
• W3044891199 title "Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates" @default.
• W3044891199 cites W1607536760 @default.
• W3044891199 cites W1874438006 @default.
• W3044891199 cites W1965031244 @default.
• W3044891199 cites W1967003781 @default.
• W3044891199 cites W2000629221 @default.
• W3044891199 cites W2007840746 @default.
• W3044891199 cites W2010207831 @default.
• W3044891199 cites W2011036663 @default.
• W3044891199 cites W2055629718 @default.
• W3044891199 cites W2066738380 @default.
• W3044891199 cites W2103870559 @default.
• W3044891199 cites W2108957284 @default.
• W3044891199 cites W2110800168 @default.
• W3044891199 cites W2125575192 @default.
• W3044891199 cites W2127069564 @default.
• W3044891199 cites W2131041950 @default.
• W3044891199 cites W2131427505 @default.
• W3044891199 cites W2141655221 @default.
• W3044891199 cites W2145061830 @default.
• W3044891199 cites W2145347536 @default.
• W3044891199 cites W2146890931 @default.
• W3044891199 cites W2149820050 @default.
• W3044891199 cites W2156701272 @default.
• W3044891199 cites W2160925670 @default.
• W3044891199 cites W2194401197 @default.
• W3044891199 cites W2467116108 @default.
• W3044891199 cites W2519957152 @default.
• W3044891199 cites W2569903330 @default.
• W3044891199 cites W2609075891 @default.
• W3044891199 cites W2760376241 @default.
• W3044891199 cites W2789400684 @default.
• W3044891199 cites W2800528359 @default.
• W3044891199 cites W2924788224 @default.
• W3044891199 cites W2944588091 @default.
• W3044891199 cites W3021512920 @default.
• W3044891199 cites W4242962261 @default.
• W3044891199 doi "https://doi.org/10.1016/j.vaccine.2020.06.062" @default.
• W3044891199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32703745" @default.
• W3044891199 hasPublicationYear "2020" @default.
• W3044891199 type Work @default.
• W3044891199 sameAs 3044891199 @default.
• W3044891199 citedByCount "31" @default.
• W3044891199 countsByYear W30448911992020 @default.
• W3044891199 countsByYear W30448911992021 @default.
• W3044891199 countsByYear W30448911992022 @default.
• W3044891199 countsByYear W30448911992023 @default.
• W3044891199 crossrefType "journal-article" @default.
• W3044891199 hasAuthorship W3044891199A5002087699 @default.
• W3044891199 hasAuthorship W3044891199A5002893062 @default.
• W3044891199 hasAuthorship W3044891199A5004378183 @default.
• W3044891199 hasAuthorship W3044891199A5005980025 @default.
• W3044891199 hasAuthorship W3044891199A5006998638 @default.
• W3044891199 hasAuthorship W3044891199A5009712443 @default.
• W3044891199 hasAuthorship W3044891199A5025263395 @default.
• W3044891199 hasAuthorship W3044891199A5026305333 @default.
• W3044891199 hasAuthorship W3044891199A5027000499 @default.
• W3044891199 hasAuthorship W3044891199A5029641140 @default.
• W3044891199 hasAuthorship W3044891199A5048700949 @default.
• W3044891199 hasAuthorship W3044891199A5054754600 @default.
• W3044891199 hasAuthorship W3044891199A5071048429 @default.
• W3044891199 hasAuthorship W3044891199A5075133911 @default.
• W3044891199 hasAuthorship W3044891199A5088571596 @default.
• W3044891199 hasConcept C104317684 @default.
• W3044891199 hasConcept C147483822 @default.
• W3044891199 hasConcept C159047783 @default.
• W3044891199 hasConcept C203014093 @default.
• W3044891199 hasConcept C22070199 @default.
• W3044891199 hasConcept C2522874641 @default.
• W3044891199 hasConcept C2776159415 @default.
• W3044891199 hasConcept C2777863537 @default.
• W3044891199 hasConcept C2779001537 @default.
• W3044891199 hasConcept C2780441014 @default.
• W3044891199 hasConcept C2780473352 @default.
• W3044891199 hasConcept C2780801004 @default.
• W3044891199 hasConcept C2780868878 @default.
• W3044891199 hasConcept C54602769 @default.
• W3044891199 hasConcept C55493867 @default.
• W3044891199 hasConcept C60987743 @default.

• next